Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JL15003 Injection in Recurrent Glioblastoma
NCT07501559Phase 2Recruiting
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Apr 2030
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of JL15003 in glioblastoma (GBM), sponsored by Jecho Biopharmaceuticals Co., Ltd.. Started Jun 2026; status: recruiting.
02
Drugs
JL15003
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07501559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07501559.